Re: SPPI valuation
It seams reasonable that SPPI can keep the doors open with what they have now [Fusilev and Zevalin]. I expect the Fusilev sales to grow with the CC indication label expansion, and this more than offset the potential "false blip" from the leucovorin shortage.
A $100m sales target seams quite reasonable for Fusilev (sales over $150m in EU), so this seams to already cover the present market cap.
Going forward:
. Zevalin growth.
I don't think anybody will value this as much because of it's long commercial failure to date. POTENTIALLY it has a lot of value, but the "prove it" crowd wins this one hands down.
. EOquin
I would say this is the meal ticket. Bladder cancer is a high prevalence, expensive (because you live a long time with it) indication. EOquin is a prodrug for the chemo mitomyacin-C, and has the nifty feature that it isn't systematically absorbed so has a good AE profile. Given the pharmacokinetics are known and the mitomyacin is well understood, this seams like a low risk (relative to the world of biotechs) candidate. Of course, it's still 3 years out.
. The rest
Same as any other bio, Oz, the taxane, and the rest of the pipeline is nice, but hard to assign any real value to.
[I know nothing about OXGN]
